As of publication, the stock has risen by over 8%, to $19.245.
According to the Zhītōng Cáijīng APP, on Friday, Hutchmed's (China) (HCM.US) stock price rose, and as of press time, the stock has risen by over 8%, to $19.245, with Hong Kong stocks closing up over 7% today. Northeast Securities research reports indicate that the company's recent R&D progress has been rapid, and multiple products have been simultaneously launched, demonstrating excellent clinical data and competitive positioning, as well as continual global product promotion. It is expected that the company's fundamental value will continue to be driven upward. In addition, the company's pipeline reserves are abundant, the product market space is broad, and overseas sales are constantly increasing. Northeast Securities maintains a "buy" rating on Hutchmed (China).